Home › NDC Lookup › Ingredients › Mefloquine Hydrochloride › 62135-0973-25
Mefloquine Hydrochloride 250 mg Tablet, 25-count — NDC 62135-0973-25 package photo

Mefloquine Hydrochloride 250 mg Tablet, 25-count

by Chartwell RX, LLC · 25 TABLET in 1 BOTTLE (62135-973-25)
NDC 62135-0973-25
🏷️ FDA NDC (as labeled) 62135-973-25 billing pads the product segment with a zero
This package
Contains25-count Cost per ea$4.14 NADAC Per package$103.51 / 25 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $5.37/unit · Part D plans $4.77/unit — full pricing hub ↓
Also comes in: 5 tablets 62135-0973-11
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 62135-973-25
Product NDC 62135-973
11-digit billing NDC 62135097325
NCPDP billing unit EA — each (per item)
RxCUI 835913
UNII 5Y9L3636O3
UPC 0362135973117, 0362135973254
Application # ANDA076175
SPL Set ID b884d22b-aae7-4f14-9a04-ae4029a229f0
Established class (EPC) Antimalarial
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-02-20
Route ORAL
Dosage form TABLET
Substance MEFLOQUINE HYDROCHLORIDE
GPI-14 13000025100310
GCN Seq No 013747
GCN 42900
HICL code 004882
Ingredient (HICL) Mefloquine Hcl
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W4
Therapeutic class — intermediate (HIC2) Antiparasitics
HIC3 code W4A
Therapeutic class — specific (HIC3) Antimalarial Drugs
AHFS code 08:30.08.00
AHFS class Antimalarials
FDB label name MEFLOQUINE HCL 250 MG TABLET
FDB brand name Mefloquine Hcl
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 62135-973-25 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 62135-0973-25. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Antimalarial class.

Pharmacologic class Antimalarial
Drug family (ATC) Methanolquinolines
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerChartwell RX, LLC
Application holderCHARTWELL RX SCIENCES LLC
FDA applicationANDA076175 (ANDA)
Labeler code62135
First marketedFeb 2022
Product typeHuman Prescription Drug
Portfolio521 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name MEFLOQUINE HCL 250 MG TABLET Ingredient Mefloquine Hcl
📗 Our plain-language guide HelloPharmacist
  • Mefloquine is an antimalarial medication, not a standard antibiotic. It works by killing malaria parasites while they're multiplying inside your red blood cells. It doesn't treat b...
  • What exactly does mefloquine do — is it an antibiotic or something else?
  • Start mefloquine one week before you arrive in a malaria-risk area. Take it once a week, on the same day every week, preferably after your biggest meal of the day — and always with...
  • I'm taking this to prevent malaria on a trip. When do I start it, and when can I stop?
📖 Read our full Mefloquine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
ShapeRound
ImprintGP;118
Size11 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 68401960MK
    Crospovidone is a synthetic polymer made from polyvinylpyrrolidone. It acts as a disintegrant, helping tablets break apart quickly in the stomach so the medicine dissolves and absorbs into the body.
  • UNII 2165RE0K14
    A plant-based thickener made from cellulose that helps control how quickly the medicine dissolves and releases its active ingredient. It also binds ingredients together and improves the tablet's texture and handling during manufacturing.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
  • UNII 7SEV7J4R1U
    A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $4.140 $103.51 / 25 tablets
Medicaid paysCMS SDUD · 12 mo $5.37 $134.20 / 25 tablets
Medicare drug plans payPart D · Q2 2026 $4.77 $119.14 / 25 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Feb 2026 May 2026 Aug 2026 $4.649 $4.069
▼ Down 11% over the last 9 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Mefloquine Hydrochloride 250 mg 00555-0171-78 Teva 25 tablets $4.140 AB Availability likely —
Mefloquine Hydrochloride 250 mgthis 62135-0973-25 Chartwell 25 tablets $4.140 AB Availability likely —
Mefloquine Hydrochloride 250 mg 50090-2396-00 A-S 10 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2022
On the market since
Feb 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 62135-0973-25, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
71
Units reimbursed last 4 qtrs
296
Gross reimbursed last 4 qtrs
$1.6K
Avg / prescription
$22.38
Avg / unit
$5.3681
Latest quarter Q1 2026
0Rx
Medicaid pays / ea
$5.3681
gross reimbursed
vs
NADAC / ea
$4.1402
acquisition cost
=
Spread
+$1.2279
+30% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
15% FFS 85% MCO
Fee-for-service · 11 Rx Managed care · 60 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 198 units · 3.5 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 98 units · 0.5 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.53.5
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Minnesota 3.5 /100k
2 New York 0.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
25 tablets this page62135-0973-25 71 Rx · $1,589
5 tablets62135-0973-11 No Medicaid data
Drug total (last 4 qtrs): 71 Rx · 296 units · $1,589 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Mefloquine Hydrochloride — the ingredient across all brands.

Top reported reactions

Anxiety37
Depression33
Insomnia33
Dizziness24
Headache20
Diarrhoea17
Nausea16

Age at onset

Adult8
Elderly2

Reporter sex

156 reports
Male · 47%
Female · 53%

Serious outcomes

Death14
Life-threatening13
Disabling12
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 6 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
62135-0973-11 5 TABLET in 1 BOTTLE (62135-973-11) — — 2024-11-15 Active
62135-0973-25 You're viewing this 25 TABLET in 1 BOTTLE (62135-973-25) $4.14 / ea $103.50 2024-11-15 Active

You're viewing the largest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in NDC 62135-0973-25?
NDC 62135-0973-25 is a 25-count package — 25 tablet in 1 bottle.
What is the difference between NDC 62135-0973-25 and NDC 62135-0973-11?
Both are Mefloquine Hydrochloride 250 mg Tablet — the drug itself is identical. NDC 62135-0973-25 is the 25-count package, while NDC 62135-0973-11 is the 5 tablets package.
What NDC number is used to bill for this package of Mefloquine Hydrochloride 250 mg Tablet?
Bill NDC 62135-0973-25 — the 11-digit billing format is 62135097325. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Medication Guide
🚨 Boxed Warning 52 words ▾

WARNING Mefloquine may cause neuropsychiatric adverse reactions that can persist after mefloquine has been discontinued. Mefloquine should not be prescribed for prophylaxis in patients with major psychiatric disorders. During prophylactic use, if psychiatric or neurologic symptoms occur, the drug should be discontinued and an alternative medication should be substituted (see WARNINGS ).

🎯 Indications and Usage 3 words ▾

INDICATIONS AND USAGE

⏱️ Dosage and Administration 3 words ▾

DOSAGE AND ADMINISTRATION

⛔ Contraindications 68 words ▾

CONTRAINDICATIONS Use of mefloquine hydrochloride tablets is contraindicated in patients with a known hypersensitivity to mefloquine or related compounds (eg, quinine and quinidine) or to any of the excipients contained in the formulation. Mefloquine hydrochloride tablets should not be prescribed for prophylaxis in patients with active depression, a recent history of depression, generalized anxiety disorder, psychosis, schizophrenia or other major psychiatric disorders, or with a history of convulsions.

⚠️ Warnings 38 words ▾

WARNINGS In case of life-threatening, serious or overwhelming malaria infections due to P. falciparum, patients should be treated with an intravenous antimalarial drug. Following completion of intravenous treatment, mefloquine may be given to complete the course of therapy.

🤒 Adverse Reactions 2 words ▾

ADVERSE REACTIONS

🆘 Overdosage 1 words ▾

OVERDOSAGE

🧬 Clinical Pharmacology 2 words ▾

CLINICAL PHARMACOLOGY

📦 How Supplied / Storage and Handling 70 words ▾

HOW SUPPLIED Mefloquine hydrochloride tablets USP, 250 mg are round, white to off white tablets, scored, debossed GP 118 on one side and plain on the reverse side, and are supplied as follows: Bottle of 5 tablets – NDC 62135-973-11 Bottle of 25 tablets – NDC 62135-973-25 Dispense in tight, light-resistant container as determined in the USP using a child-resistant closure. Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature).

📋 Description 111 words ▾

DESCRIPTION Mefloquine hydrochloride is an antimalarial agent available as 250 mg tablets of mefloquine hydrochloride (equivalent to 228.0 mg of the free base) for oral administration. Mefloquine hydrochloride is a 4-quinolinemethanol derivative with the specific chemical name of (R*, S*)-(±)-α-2-piperidinyl-2,8-bis (trifluoromethyl)-4-quinolinemethanol hydrochloride. It is a 2-aryl substituted chemical structural analog of quinine.

The drug is a white to almost white crystalline compound, slightly soluble in water. Mefloquine hydrochloride has a calculated molecular weight of 414.78 and the following structural formula: Mefloquine Hydrochloride Tablets USP, 250 mg meets USP Dissolution Test 2. The inactive ingredients are crospovidone, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, pregelatinized starch and talc. "Image Description"

💬 Medication Guide ~3 min read ▾

Print Medication Guides at: www.chartwellpharma.com/medguides. MEDICATION GUIDE Mefloquine Hydrochloride Tablets, USP Important: Your doctor or pharmacist will give you an Information Wallet Card along with this Medication Guide. It has important information about mefloquine and should be carried with you at all times while you take mefloquine.

What is the most important information I should know about mefloquine? Mefloquine can cause serious side effects, including: 1. Heart Problems.

Do not take halofantrine (used to treat malaria) or ketoconazole (used for fungal infections) with mefloquine or within 15 weeks of your last dose of mefloquine. You may get serious heart problems (problems with the electrical system of your heart called QT prolongation) that can lead to death. Do not take quinine (Qualaquin) or quinidine (used to treat malaria or irregular heart beat) with mefloquine.

You may get serious heart problems. 2. Mental problems.

Symptoms of serious mental problems may include: severe anxiety paranoia (feelings of mistrust towards others) hallucinations (seeing or hearing things that are not there) depression feeling restless unusual behavior feeling confused Some people who take mefloquine think about suicide (putting an end to their life). Some people who were taking mefloquine committed suicide. It is not known if mefloquine was responsible for those suicides.

If you have any of these serious mental problems, or you develop other serious side effects or mental problems, you should contact your doctor right away as it may be necessary to stop taking mefloquine and use a different medicine to prevent malaria. 3. Problems with your body’s nervous system.

Symptoms of serious nervous system problems may include: dizziness a feeling that you or things around you are moving or spinning (vertigo) loss of balance ringing sound in your ears (tinnitus) convulsions (seizures) in people who already have seizures (epilepsy) convulsions (seizures) in people who take quinine or chloroquine (used to treat malaria) with mefloquine. Do not take quinine (Qualaquin) or chloroquine (Aralen) with mefloquine. unable to sleep (insomnia) Dizziness, vertigo, tinnitus, and loss of balance can go on for months or years after mefloquine is stopped or may become permanent in some people.

Important: You need to take malaria prevention medicine before you travel to a malaria area, while you are in a malaria area, and after you return from a malaria area. If you are told by a doctor to stop taking mefloquine because of the side effects or for other reasons, you will need to take different malaria medicine. If you do not have access to a doctor or to another medicine and have to stop taking mefloquine, leave the malaria area and contact a doctor as soon as possible because leaving the malaria area may not protect you from getting malaria.

You will still need to take a malaria prevention medicine for another 4 weeks after you leave the malaria area. What is Mefloquine? Mefloquine is a prescription medicine used to prevent and treat malaria.

Malaria can be a life-threatening infection. Mefloquine does not work for all types of malaria. It is not known if mefloquine is safe and effective in children under 6 months old for the treatment of malaria.

It is not known how well mefloquine works to prevent malaria in children weighing less than 44 pounds (20 kilograms). Who should not take Mefloquine? Do not take Mefloquine if you have: depression or had depression recently had recent mental problems, including anxiety disorder, schizophrenia, or psychosis (losing touch with reality) seizures or had seizures (epilepsy or convulsions) an allergy to quinine, quinidine, mefloquine or any ingredients in mefloquine.

See the end of this Medication Guide for a complete list of ingredients in mefloquine. Talk to your doctor before you take mefloquine if you have any of the medical conditions listed above. What should I tell my doctor before taking mefloquine?

Before…

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 62135-0969-90 · Chartwell 62135-0975-20 · Chartwell →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.